Navigation Links
Cardiogenesis Reports Third Quarter 2008 Results

IRVINE, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP), a leading developer of surgical products used in the treatment of patients suffering from severe angina, today reported financial results for its third quarter ended September 30, 2008.

Third Quarter Financial Results

Sales in the third quarter of 2008 totaled $2,618,000, a 25% decrease from the prior year third quarter sales of $3,486,000. The lower revenue in the current year quarter is primarily attributable to a $534,000, or 59%, decrease in capital sales, and a $326,000, or 14%, decrease in disposable handpiece revenue as compared with the prior year quarter.

Sales in the first nine months of 2008 totaled $9,719,000, an increase of approximately $427,000 or 5% from sales of $9,292,000 in the first nine months of 2007. The year to date increase as compared with the prior year period is primarily attributable to a $712,000, or 38%, increase in capital sales offset by a $255,000, or 4%, decrease in disposable handpiece revenue.

The Company reported a third quarter 2008 operating loss of $310,000 as compared with an operating income of $679,000 in the prior year quarter. The Company's net loss for the quarter was $308,000, or $0.01 per diluted share, as compared with a net income of $590,000, or $0.01 per diluted share, in the 2007 third quarter.

For the first nine months of 2008, Cardiogenesis reported operating income of $235,000 as compared with $888,000 for the same period in the prior year. Net income for the first nine months of 2008 was $258,000, or $0.01 per diluted share, compared with $662,000, or $0.01 per diluted share, for the first nine months of 2007.

Gross profit decreased by $603,000 to $2,144,000 in the current year quarter as compared with $2,747,000 for the 2007 third quarter. Gross margin was 82% of net revenues for the quarter ended September 30, 2008 as compared with a 79% gross margin in the third quarter of 2007. The increase in gross margin for the three month period is primarily attributable to an increase in the average selling price of disposable handpieces.

Gross profit increased by $751,000 to $8,130,000 for the nine months ended September 30, 2008, as compared with $7,379,000 for the nine months ended September 30, 2007. For the nine months ended September 30, 2008, gross margin was 84% of net revenues as compared to 79% of net revenues for the nine months ended September 30, 2007. The increase in gross profit and gross margin for the nine month period is primarily attributable to higher average selling prices for both laser and disposable handpiece units. In addition, during the second quarter of 2008, the company recognized $234,000 of deferred revenue for which there was no associated cost of goods sold.

Research and development costs ("R&D") were $165,000 in the third quarter of 2008 as compared with $103,000 in the 2007 third quarter. Year to date, R&D expenses of $633,000 were $21,000 or 3% higher than the prior year period of $612,000.

Sales and marketing ("S&M") expenses of $1,536,000 in the quarter ended September 30, 2008 increased $290,000, or 23%, compared with $1,246,000 for the quarter ended September 30, 2007. For the nine months ended September 30, 2008, S&M expenditures totaled $4,858,000, an increase of $1,590,000, or 49%, compared with $3,268,000 for the nine months ended September 30, 2007. The increase for both the quarter and year to date periods is primarily due to higher compensation expenses related to investments made to strengthen the sales and marketing organization.

General and administrative expenditures ("G&A") for the quarter ended September 30, 2008 totaled $753,000 as compared to $719,000 during the quarter ended September 30, 2007. For the nine months ended September 30, 2008, G&A totaled $2,404,000 as compared to $2,611,000 for the nine months ended September 30, 2007. This reduction of $207,000, or 8%, is primarily attributable to lower insurance expense in the current year.

Richard Lanigan, Cardiogenesis President stated, "To leverage the investments we have made in our sales organization, we are undertaking a major marketing initiative to drive greater awareness of the benefits of TMR within the cardiology community. As we reported in October we began with a successful kick-off at the recent Transcatheter Cardiovascular Therapeutics (TCT) meeting." Mr. Lanigan explained, "Although intraoperative TMR procedures are performed by the cardiothoracic surgeon, it is the cardiologist that manages the patients and with that patient determines treatment strategies that may include medical management, percutaneous intervention or surgery. Educating cardiologists on the discrete current indications for TMR, as well as future applications is critical to garner their support and referrals for TMR. Engaging them directly will be critical to achieving the clinical and commercial potential of our technology and we plan on providing more color on the topic during our earnings call."

About Cardiogenesis Corporation

Cardiogenesis is a medical device company specializing in the treatment of cardiovascular disease and is a leader in devices that treat severe angina. The Company's market leading holmium:YAG laser system and single use fiber-optic delivery systems are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR).

For more information on Cardiogenesis and its products, please visit the Company's website at or the direct to patient website at

Safe Harbor Statement

With the exception of historical information, the statements set forth above include forward-looking statements. Any forward-looking statements in this news release related to the possible effectiveness of the Company's technologies and the effect of such technologies on the Company's sales, profitability, the adoption of its technology and products and FDA clearances are based on current expectations and beliefs and are subject to numerous risks and uncertainties, many of which are outside the Company's control, that could cause actual results to differ materially. Factors that could affect the accuracy of these forward-looking statements include, but are not limited to: any inability by the Company to sustain profitable operations or obtain additional financing on favorable terms if and when needed; any failure to obtain required regulatory approvals; failure of the medical community to expand its acceptance of TMR procedures; possible adverse governmental rulings or regulations, including any FDA regulations or rulings; the Company's ability to comply with international and domestic regulatory requirements; possible adverse Medicare or other third-party reimbursement policies or adverse changes in those policies; any inability by the Company to ship product on a timely basis; the Company's ability to manage its growth; the effects of recent disruptions in global credit and equity markets and other adverse economic developments that could adversely affect the market for our products or our ability to raise needed financing; actions by our competitors; and the Company's ability to protect its intellectual property. Other factors that could cause Cardiogenesis' actual results to differ materially are discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007 and the Company's other recent SEC filings. The Company disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.



(in thousands, except per share amounts)


Three months ended Nine months ended

September 30, September 30,

2008 2007 2008 2007

Net revenues $2,618 $3,486 $9,719 $9,292

Cost of revenues 474 739 1,589 1,913

Gross profit 2,144 2,747 8,130 7,379

Operating expenses:

Research and development 165 103 633 612

Sales and marketing 1,536 1,246 4,858 3,268

General and administrative 753 719 2,404 2,611

Total operating expenses 2,454 2,068 7,895 6,491

Operating (loss) income (310) 679 235 888

Other income (expense):

Interest expense (1) (10) (22) (59)

Interest income 13 29 55 94

Non-cash interest expense -- (13) -- (89)

Change in fair value of

derivatives -- (133) -- (323)

Other non-cash income, net -- 38 -- 151

Total other income (expense), net 12 (89) 33 (226)

(Loss) income before

income taxes (298) 590 268 662

Tax provision 10 -- 10 --

Net (loss) income $(308) $590 $258 $662

Net (loss) earnings per share:

Basic $(0.01) $0.01 $0.01 $0.01

Diluted $(0.01) $0.01 $0.01 $0.01

Weighted average shares


Basic 45,292 45,274 45,292 45,274

Diluted 45,292 45,274 45,328 45,274



(in thousands)

September December

30, 2008 31, 2007

(unaudited) (audited)


Current assets:

Cash and cash equivalents $3,439 $2,824

Accounts receivable, net of allowance for

doubtful accounts of $49 and $28,

respectively 1,319 1,763

Inventories 1,380 1,602

Prepaids and other current assets 466 486

Total current assets 6,604 6,675

Long-term investments in marketable securities 75 --

Property and equipment, net 341 457

Other assets, net 27 27

Total assets $7,047 $7,159


Current liabilities:

Accounts payable $338 $169

Accrued liabilities 1,124 1,458

Deferred revenue 902 1,210

Current portion of capital lease obligation 8 12

Total current liabilities 2,372 2,849

Capital lease obligation, less current portion 14 19

Total liabilities 2,386 2,868

Commitments and Contingencies

Shareholders' equity:

Preferred stock:

no par value; 5,000 shares authorized;

none issued and outstanding -- --

Common stock:

no par value; 75,000 shares authorized;

45,314 and 45,274 shares issued

and outstanding, respectively 173,938 173,826

Accumulated deficit (169,277) (169,535)

Total shareholders' equity 4,661 4,291

Total liabilities and shareholders' equity $7,047 $7,159

SOURCE Cardiogenesis Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results
2. Cardiogenesis Corporation to Report Third Quarter 2007 Results on November 14th
3. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
4. Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results
5. China Biologic Products Reports Strong Third Quarter 2008 Results
6. Imagenetix, Inc. Reports Second Quarter and Six Month Results
7. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
8. China-Biotics, Inc. Reports Second Quarter 2009 Financial Results
9. Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
10. Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year
11. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published ... frozen and fresh in vitro fertilization (IVF) transfer cycles. The multi-center ... success. , After comparing the results from the fresh and frozen transfer cohorts, ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO of ... Rotary Club. The event entitled “Stem Cells and Their Regenerative Powers,” ... Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
(Date:10/7/2017)... Phoenix, Arizona (PRWEB) , ... ... ... than 15 years’ experience providing advanced instruments and applications consulting for microscopy ... the in-house expertise in application consulting, Nanoscience Analytical offers a broad range ...
Breaking Biology Technology:
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
(Date:3/24/2017)... 2017 The Controller General of Immigration from Maldives ... Algeen have received the prestigious international IAIR Award for the most ... Reading ... Maldives ... Abdulla Algeen (small picture on the right) have received the IAIR award ...
(Date:3/23/2017)... 2017 Research and Markets has announced the ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... of around 8.8% over the next decade to reach approximately $14.21 ... market estimates and forecasts for all the given segments on global ...
Breaking Biology News(10 mins):